Cyclerion Therapeutics Inc.
13F holders, Q2 2025 (June 30)17holders −1
1new positions
2sold out
$2.91avg. 13F price*
At the end of Q2 2025, 17 institutions reported holding Cyclerion Therapeutics Inc. in their 13F filings, down 1 from Q1 2025. 1 opened new positions and 2 sold out. The largest holders were Tyndall Capital Partners L P ($452K), Siren, L.L.C. ($338K) and Geode Capital Management, LLC ($95K).
- Company
- Cyclerion Therapeutics Inc.
- CUSIP
- 23255M204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $32 |
| Exits | 2 | $53 |
All 13F filers, Q1 2025 → Q2 2025: 2,857 shares bought and 13,433 shares sold, net −10,576 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Tyndall Capital Partners L P | 100.00% | Reduce -5.8% | 155,187 | $452K |
| Siren, L.L.C. | 0.02% | No change | 116,155 | $338K |
| Geode Capital Management, LLC | 0.00% | Add +3.6% | 32,735 | $95K |
| Vanguard Group Inc. | 0.00% | No change | 23,490 | $68K |
| BlackRock, Inc. | 0.00% | No change | 16,797 | $49K |
| UBS Group AG | 0.00% | Reduce -25.2% | 9,727 | $28K |
| FMR LLC | 0.00% | Reduce -4.0% | 4,740 | $14K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +162.1% | 2,763 | $8K |
| Morgan Stanley | 0.00% | No change | 649 | $2K |
| Group One Trading LLC | 0.00% | Reduce -64.4% | 192 | $559 |
| Osaic Holdings, Inc. | 0.00% | No change | 130 | $378 |
| Activest Wealth Management | 0.00% | No change | 100 | $291 |
| MAI Capital Management | 0.00% | No change | 100 | $291 |
| Bank of America Corp. | 0.00% | Add +26.3% | 24 | $70 |
| SBI Securities Co., Ltd. | 0.00% | No change | 11 | $32 |
| Pandora Wealth, Inc. | 0.00% | New | 11 | $32 |
| BNP Paribas Financial Markets | 0.00% | No change | 5 | $15 |
"% of holder's portfolio" is CYCLERION THERAPEUTICS INC's weight in each manager's 13F, not the share of Cyclerion Therapeutics Inc. the manager owns.